University of Sussex
Browse

File(s) not publicly available

Riluzole protects against glutamate-induced slowing of neurofilament axonal transport

journal contribution
posted on 2023-06-08, 13:40 authored by Alison Stevenson, Darran M Yates, Catherine Manser, Kurt J De Vos, Alessio Vagnoni, Nigel LeighNigel Leigh, Declan M McLoughlin, Christopher C J Miller
Riluzole is the only drug approved for the treatment of amyotrophic lateral sclerosis (ALS) but its precise mode of action is not properly understood. Damage to axonal transport of neurofilaments is believed to be part of the pathogenic mechanism in ALS and this has been linked to defective glutamate handling and increased phosphorylation of neurofilament side-arm domains. Here, we show that riluzole protects against glutamate-induced slowing of neurofilament transport. Protection is associated with decreased neurofilament side-arm phosphorylation and inhibition of the activities of two neurofilament kinases, ERK and p38 that are activated in ALS. Thus, the anti-glutamatergic properties of riluzole include protection against glutamate-induced changes to neurofilament phosphorylation and transport

History

Publication status

  • Published

Journal

Neuroscience Letters

ISSN

0304-3940

Publisher

Elsevier

Issue

2

Volume

454

Page range

161-4

Department affiliated with

  • Clinical and Experimental Medicine Publications

Full text available

  • No

Peer reviewed?

  • Yes

Legacy Posted Date

2012-11-15

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC